Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Selgantolimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 known ✓ | Q9NR97 | 15/20 | 1.00 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Selgantolimod SCHEMBL29368858 | 1.00 | TLR8 (1.00) | TLR8TLR7KCNH2NLRP3 | |
| Selgantolimod SCHEMBL31141439 | 1.00 | TLR8 (1.00) | TLR8TLR7KCNH2NLRP3 | |
| Selgantolimod SCHEMBL18109719 | 1.00 | TLR8 (1.00) | TLR8TLR7KCNH2NLRP3 | |
| Selgantolimod SCHEMBL18109405 | 1.00 | TLR8 (1.00) | TLR8TLR7KCNH2NLRP3 | |
| Selgantolimod SCHEMBL22613603 | 0.99 | TLR8 (0.98) | TLR8TLR7KCNH2NLRP3 | |
| Selgantolimod SCHEMBL22558375 | 0.99 | TLR8 (0.98) | TLR8TLR7KCNH2NLRP3 | |
| Selgantolimod SCHEMBL22558518 | 0.99 | TLR8 (0.98) | TLR8TLR7KCNH2NLRP3 | |
| Selgantolimod SCHEMBL28692784 | 0.99 | TLR8 (0.98) | TLR8TLR7KCNH2NLRP3 | |
| SCHEMBL18109386 | 0.97 | TLR8 (0.94) | TLR8TLR7KCNH2NLRP3 | |
| SCHEMBL18109383 | 0.97 | TLR8 (0.94) | TLR8TLR7KCNH2NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4458416-A2 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | Gilead Sciences, Inc. (US) | 2024-11-06 | — | — | EP | claimed |
| EP-3956328-B1 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | GILEAD SCIENCES INC (US) | 2024-09-18 | — | — | EP | claimed |
| EP-3956329-B9 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | GILEAD SCIENCES INC (US) | 2024-04-17 | — | — | EP | claimed |
| EP-3956329-B1 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | GILEAD SCIENCES INC (US) | 2024-01-10 | — | — | EP | claimed |
| US-11583531-B2 | Solid forms of a toll-like receptor modulator | GILEAD SCIENCES, INC. (US) | 2023-02-21 | — | — | US | claimed |
| US-11396509-B2 | Solid forms of a toll-like receptor modulator | GILEAD SCIENCES, INC. (US) | 2022-07-26 | — | — | US | claimed |
| CN-113906023-A | Solid forms of a TOLL-like receptor modulator | 吉利德科学公司 | 2022-01-07 | — | — | CN | claimed |
| CN-113767098-A | Solid forms of Toll-like receptor modulators | 吉利德科学公司 | 2021-12-07 | — | — | CN | claimed |
| US-20200345738-A1 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | GILEAD SCIENCES, INC. (US) | 2020-11-05 | — | — | US | claimed |
| US-20200347051-A1 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | GILEAD SCIENCES, INC. | 2020-11-05 | — | — | US | claimed |
| US-12590089-B2 | Processes for preparing toll-like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12590089-B2 | Processes for preparing toll-like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12377100-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4458416-A3 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | Gilead Sciences, Inc. (US) | 2025-04-02 | — | — | EP | disclosed |
| EP-4484426-A1 | PYRIMIDO AROMATIC RING COMPOUND AND USE THEREOF IN DRUG | Sunshine Lake Pharma Co., Ltd. (CN) | 2025-01-01 | — | — | EP | disclosed |
| US-20170071944-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
| EP-3097102-A1 | TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS | Gilead Sciences, Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590089-B2 | Processes for preparing toll-like receptor modulator compounds | TLR8, MYD88, TLR6 | TLR8 1/4885TLR7 9/4885KCNH2 2961/4885 |
| US-20200345738-A1 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | TLR4, TLR3, TLR2 | TLR8 9/4885TLR7 7/4885KCNH2 3535/4885 |
| US-20200347051-A1 | SOLID FORMS OF A TOLL-LIKE RECEPTOR MODULATOR | TLR4, TLR3, TLR2 | TLR8 9/4885TLR7 7/4885KCNH2 3521/4885 |
| US-12377100-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | TLR8 1/4885TLR7 9/4885KCNH2 4348/4885 |
| US-11396509-B2 | Solid forms of a toll-like receptor modulator | TLR4, TLR3, TLR2 | TLR8 9/4885TLR7 7/4885KCNH2 3521/4885 |
| US-11583531-B2 | Solid forms of a toll-like receptor modulator | TLR4, TLR3, TLR2 | TLR8 9/4885TLR7 7/4885KCNH2 3535/4885 |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | TLR8 1/4885TLR7 9/4885KCNH2 4348/4885 |
| US-20170071944-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR8, TLR3, TLR6 | TLR8 1/4885TLR7 4/4885KCNH2 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.